Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir vs lopinavir/ritonavir for treatment of COVID-19
IRCT20200506047323N3Phase 3Completed
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of favipiravir and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hormozgan University of Medical Sciences. Started Jul 2020; status: completed.
02
Drugs
favipiravirlopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200506047323N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200506047323N3.